BLS Pharmaceuticals Limited Overview
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Employees (headcount) | — | — | — |
| Employee benefits and labour hire expense (A$ M) | — | 5.13 | 11.30 |
| Superannuation contributions (A$ M) | — | 0.39 | 0.78 |
Source: FY2026 Annual Report (restated FY2025 comparatives). Headcount not disclosed; superannuation expense doubling is a reasonable proxy for roughly doubled Australian payroll.
BLS Pharmaceuticals is an Australian-headquartered, GMP-licensed downstream pharmaceutical manufacturer and wholesaler specialising in controlled and "special access" medicines—principally medicinal cannabis, with an emerging position in MDMA and psilocybin finished-dose products. Its core asset is a multi-jurisdictional licence stack (TGA, Office of Drug Control, Queensland Health) and a Brisbane manufacturing platform the company estimates can support over A$250m of annual revenue. Rather than cultivating or prescribing, BLS converts third-party active pharmaceutical ingredients into compliant finished doses (flower, pastilles, oils, vapes, capsules) for brand owners, clinics and distributors, and sells its own Dr Watson® brand. Revenue rose from A$5.2m in FY2023 to A$74.2m in FY2026 with A$15.4m NPAT, and FY2027 guidance is A$105–115m. Expansion levers include a A$50m German supply contract with ADREXpharma, a Scottish GMP facility, Latin American exports, and partnerships with Aurora Cannabis and Curaleaf International. Key risks are regulatory dependence, customer concentration and working-capital intensity.
Company's own description (FY2026 Annual Report)
The FY2026 Directors' Report describes BLS Pharmaceuticals as an international Australian life sciences company headquartered in Sydney and the parent of the Breathe Life Sciences group, whose subsidiaries are licensed to manufacture, import, export and supply controlled drugs and prescription medicines including cannabis, MDMA and psilocybin, supported by a multi-national licence stack. In Australia, subsidiary BLS Wholesalers Pty Ltd is described as the market-leading manufacturer of medicinal cannabis, MDMA and psilocybin products, licensed by the TGA, ODC and Queensland Health. In the UK, the subsidiary is transitioning into manufacture and supply via third-party licences until its own facility is licensed. In Germany, supply flows through local partner ADREXpharma, which holds the requisite local licences. Across all markets, the stated strategy is to replicate the Australian model, building brand equity under the Breathe Life Sciences (B2B) and Dr Watson® (patient/consumer-facing) brands.
The CEO's report articulates the vision as becoming the global leader in breakthrough and investigational medicines containing cannabis, MDMA, psilocybin and other APIs, and the strategy as becoming the market-leading manufacturer and wholesale supplier in each market served.
Business model
| Revenue stream | Description | Recognition (FY2026 accounting policy) |
|---|---|---|
| Sale of goods (own brands) | Dr Watson® medicinal cannabis and OTC products; BLS-branded medicines | Point in time (QA release + transfer of risks/rewards) |
| Contract / white-label manufacturing | Finished-dose manufacture for brand owners (e.g., NectarTek, Aurora Cannabis, Curaleaf QMID cartridges) | Point in time; bill-and-hold permitted under strict criteria |
| Pharmaceutical procurement / API sourcing | Sourcing raw materials and APIs from suppliers on five continents | Bundled within goods sales |
| Storage and distribution | Controlled-drug storage, warehousing, wholesale distribution | Over time (output method) |
| Import/export and market access | ARTG export registrations (24 products registered FY2026), export to UK, Germany, Costa Rica | Bundled within goods sales |
| Probiotic licensing/wholesale (legacy) | Lactobacillus fermentum PCC® wholesale via Chr. Hansen and Nu Skin | Point in time; A$554,868 revenue in FY2026 |
The Operations Report describes five connected capabilities: Sourcing/Procurement → Manufacture → Compliance & Regulatory → Import/Export → Distribute. BLS explicitly positions itself as a downstream manufacturer and distributor, avoiding the capital and agricultural risk of cultivation and not owning prescribing channels. Revenue streams include:
Payment terms: customers typically pay a deposit (generally 50%) prior to completion, with the balance on shipment; larger customers are on 30-day terms (FY2026 Annual Report, Note 1(D)). Contract liabilities (customer deposits) were A$2.66m at 30 June 2026.
Revenue model mix: predominantly product/contract manufacturing revenue (point-in-time); a small storage and distribution service component recognised over time; negligible royalty income (other income A$68k in FY2026). There is no subscription revenue. The precise split between own-brand and contract manufacturing revenue is not publicly disclosed.
Value chain position
BLS sits in the mid-to-downstream segment of the regulated medicines value chain: between API producers/cultivators (e.g., Aurora Cannabis, Cayman Chemical for psychedelic APIs) and prescribers, clinics, pharmacies and distributors (e.g., NectarTek clinics, ADREXpharma). Its moat is regulatory: few Australian companies hold the combination of GMP, controlled-drug manufacturing, import/export and wholesale licences across cannabis, MDMA and psilocybin.
Customer types and end-markets
| Customer type | Examples (disclosed) | End-market |
|---|---|---|
| Medicinal cannabis brand owners / clinics | NectarTek (exclusive manufacturer agreement) | Australian prescribed medicinal cannabis (SAS-B, Authorised Prescriber) |
| International cultivators/manufacturers | Aurora Cannabis (Nasdaq/TSX-listed), Curaleaf International | Australia, UK, Germany |
| International distributors | ADREXpharma (Germany), Remidose LATAM SRL (Costa Rica, Panama) | German pharmacy channel; Central American regulated cannabis |
| Authorised prescribers / psychedelic therapy providers | Unnamed Australian clinics; clinical trials for treatment-resistant PTSD | Australian psychedelic-assisted therapy (MDMA for PTSD; psilocybin for TRD) |
| Consumer / OTC retail | Harrods pharmacy (London), Ideal World TV shopping (UK), Amazon (UK, historically US/Japan) | OTC supplements |
| Nutraceutical partners | Chr. Hansen (Denmark), Nu Skin Enterprises (USA) | Probiotic supplements (PCC®) |
Independent characterisation
BLS is best understood as a licensed contract development and manufacturing organisation (CDMO) plus wholesaler for scheduled medicines, with a growing own-brand overlay. Its economics resemble a specialty CDMO: high operating leverage on a largely fixed leasehold facility, meaningful raw-material pass-through (raw materials consumed were ~49.5% of FY2026 revenue), and working-capital intensity driven by inventory held for continuity of supply. The FY2026 result (26% adjusted EBITDA margin) demonstrates operating leverage, but the revenue base remains heavily concentrated in Australian medicinal cannabis, a market exposed to regulatory and pricing changes. The psychedelic franchise is strategically important but commercially immaterial today (e.g., initial psilocybin sales of 250 doses, sufficient for ~60 patients).
Strategy
Stated strategy themes (FY2026 Annual Report)
Vision: "Redefining medicine for a healthier tomorrow" — to be the global leader in breakthrough and investigational medicines containing cannabis, MDMA, psilocybin and other APIs.
Four strategic priorities (Operations Report):
-
Scale the established Australian platform — lift Brisbane utilisation (capacity >A$250m revenue p.a.) via additional shifts without proportionate capex; grow existing customers; broaden dose forms.
-
Build an integrated international GMP footprint — Australia as principal base; Scotland for UK/EU supply; convert German relationships into recurring supply; partner with local importers elsewhere rather than replicating infrastructure.
-
Become a preferred downstream pharmaceutical partner — offer GMP finished-dose manufacture, controlled-drug handling, import/export, wholesale and regulatory support to API holders lacking licences (Aurora cited as proof point).
-
Broaden product categories — MDMA, psilocybin, Dr Watson portfolio near term; ibogaine, peptides, ibuprofen and other approved medicines under evaluation; longer-term proprietary formulations, combination medicines, delivery formats and process IP.
Overarching principle: disciplined growth—increase utilisation of existing platform before committing material capital; selective, accretive partnerships or acquisitions only.
Initiatives announced in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| Australian in-house manufacturing | Aug 2024 | Start of BLS-owned GMP manufacturing | Complete; scaling |
| Capacity expansion | H1 FY2026 | Clean rooms +100%; storage +200%; pastille capacity up to 6m/month | Complete |
| German market entry | Jun 2025 → May 2026 | €3.2m Adrex agreement expanded to ~A$50m two-year exclusive Dr Watson distribution | Executing |
| Frankfurt dual listing | Oct 2025 | PR8.F for European capital access | Complete |
| Scotland GMP facility | Oct 2025–Dec 2026 | SOSE-backed (£500k loan; grants up to ~£348k—£848,250 total SOSE package) facility; capex A$2.1m to 30 June 2026 | Construction/commissioning |
| LATAM entry | Dec 2025 → May 2026 | Remidose Costa Rica/Panama | First sales FY2026 |
| Curaleaf QMID | Nov 2025 | Exclusive device + cartridge supply | Launched |
| Aurora Cannabis manufacturing | Apr 2026 | Oils and vapes for AU, expanding to UK and DE | Commenced |
| Cayman Chemical referral | Jul 2026 | Psychedelic API customer referrals | Signed |
| Trexapharm exploration | FY2026 | Nasal spray and injectable formats | Exploratory |
| PTSD combination medicine / drug development pipeline | FY2026 | Accelerate clinical evidence for BLS-owned MDMA and psilocybin medicines (PTSD, TRD) | Early stage |
| US export ambition | FY2026 | Work toward export of MDMA/psilocybin capsules to the US following breakthrough-therapy designations | Aspirational; no US presence |
| Corporate rebrand and consolidation | Jun–Jul 2026 | Name change to BLS Pharmaceuticals; 1:10 consolidation | Complete |
| Westpac overdraft | Post 30 Jun 2026 | A$3m undrawn facility | Complete |
ESG/sustainability commitments and formal cost programmes: none publicly disclosed.
Guidance and medium-term targets
| Metric | FY2025 actual | FY2026 initial guidance | FY2026 upgraded guidance | FY2026 actual | FY2027 guidance |
|---|---|---|---|---|---|
| Revenue (A$ M) | 28.4 | 65–75 | 65–75 | 74.2 | 105–115 |
| Adjusted EBITDA (A$ M) | 7.0 | 11.5–13.5 | 16.5–19.0 | 19.0 | ~24–30 implied |
| Adjusted EBITDA margin (%) | 25 | — | — | 26 | 23–26 |
FY2027 implied adjusted EBITDA (A$24.2–29.9m) is derived by applying the margin range to the revenue range. Longer-term capacity statements: c.A$250m p.a. Australian revenue capacity plus c.A$150m from the UK facility (company estimates, not targets).
Products & Services
Medicinal cannabis (principal commercial category)
| Product / platform | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Dr Watson® medicinal cannabis flower | Own-brand GMP dried flower; three flower products exported to Costa Rica via Remidose | Patients via prescribers/pharmacies (AU); distributors (DE, LATAM) | Australian sales ongoing; Costa Rica first sale >A$0.5m (FY2026) | — |
| Dr Watson® medicinal cannabis (Germany) | Exclusive distribution by ADREXpharma under two-year ~A$50m agreement | German pharmacy network | Agreement May 2026 | — |
| THC pastilles | Pharmaceutical-grade THC pastilles; company describes the world's largest GMP-certified cannabis pastille facility (capacity up to 6 million pastilles/month) | Brand owners; Remidose (LATAM) | Scaled during FY2026 | — |
| Oils (sublingual) | Cannabis oils manufactured for own and third-party brands; Aurora initial scope >5,000 units | Aurora Cannabis; Australian patients | FY2026 | — |
| Vape / inhalable products | Cannabis liquid inhalants; Aurora initial sales >20,000 vape units; expansion to UK and Germany | Aurora Cannabis; prescribers | FY2026 | — |
| Que Medical Inhalation Device (QMID) | Exclusive Australian import, manufacture (including API and cartridge filling) and supply for Curaleaf International; recurring device + cartridge model | Authorised prescribers, SAS-B, pharmacies | TGA import approval 1 Oct 2025; ODC authorisation 27 Oct 2025; launch Nov 2025 | — |
| White-label / contract manufacturing | Finished-dose manufacture for third-party brands (e.g., NectarTek exclusive for AU, UK, DE) | Clinics, brand owners | NectarTek agreement April 2025 (≥A$7m FY2026 committed) | Contract-specific |
| ARTG-registered export products | 24 cannabis-based medicinal products registered on ARTG for export in FY2026 | Export markets (UK, DE, LATAM) | FY2026 | Not applicable |
Psychedelic medicines
| Product | Description | Target | Status |
|---|---|---|---|
| BLSMD40 / BLSMD100 (MDMA capsules) | GMP-manufactured MDMA capsules (40mg / 100mg nominal from product codes); first Australian-made GMP-certified MDMA capsules | Authorised Prescribers (PTSD); clinical trials in treatment-resistant PTSD | Commercial batch production from July 2025; first commercial supply H1 FY2026; 400+ patient doses supplied (per Dr. Reuter Investor Relations, Feb 2026) |
| BLSPSIL25 (psilocybin capsules) | GMP psilocybin capsules (25mg nominal from product code) | Authorised Prescribers (treatment-resistant depression) | Initial sale of 250 doses (~60 patients over 12 months) in FY2026 |
| Combination medicine for PTSD | Proprietary combination medicine under development | PTSD patients | Announced FY2026; pre-commercial |
| Psychedelic API access (Cayman Chemical referral) | Cayman Chemical refers psilocybin/MDMA API customers to BLS for patient-ready dosage manufacture | Global | Agreement 21 Jul 2026 |
New dose forms and pipeline categories
| Initiative | Description | Status |
|---|---|---|
| Trexapharm exploratory agreement | Nasal spray and injectable dose forms | Exploratory (FY2026) |
| Ibogaine, peptides, ibuprofen | Evaluated as potential new regulated product categories | Evaluation; company states these are not committed programs |
| Novel delivery mechanisms / proprietary formulations | IP development in dose forms and delivery for MDMA and psilocybin | Early stage |
Consumer health / OTC
| Product | Description | Channel | Status |
|---|---|---|---|
| Dr Watson® OTC supplements | Over-the-counter supplement range | Harrods pharmacy (London); Ideal World (UK TV shopping, channel 51); Amazon | Active (launch dates not disclosed) |
| Lactobacillus fermentum PCC® | Proprietary probiotic strain for gut health/immune supplements | Chr. Hansen (global distribution); Nu Skin (USA) | Legacy; A$0.55m FY2026 revenue |
| Progastrim (nano-encapsulated) | Probiotic product update with improved shelf life (planned 2H 2023 launch) | BLS e-commerce | Current status not disclosed |
| BLS Clinics | Online telehealth service launched June 2023 | Patients | Current status not disclosed |
| Mirai Solution / CanXChange | Japan consumer health brand / platform referenced in Morningstar profile | Japan | Current status not disclosed |
Services
| Service | Description |
|---|---|
| Pharmaceutical input sourcing / procurement | Global API and raw material sourcing (suppliers on five continents) |
| Product development | Formulation and dose-form development for clients |
| Packaging and QA release | GMP quality assurance |
| Controlled-drug storage | Storage capacity increased 200% in H1 FY2026 |
| Import / export | ODC permits; ARTG export registrations |
| Wholesale distribution and market access | Supply to pharmacies, prescribers and distributors |
Financial Narrative
Basis: FY2022 reflects Breathe Life Sciences standalone (reverse-acquisition accounting acquirer); FY2023 includes legacy Bioxyne only from 19 May 2023. FY2025 figures are the restated comparatives in the FY2026 Annual Report.
Income statement
Sources and derivations: FY2023 revenue A$5,160,538 and FY2022 A$463,636 (FY2023 Appendix 4E); FY2024 revenue A$9,655,752 and loss A$13,325,050 (FY2025 Appendix 4E); FY2022–FY2024 gross profit, EBIT and PBT per Stockopedia (FY2024 revenue there is A$9.33m—discrepancy vs. A$9.66m in the Appendix 4E). FY2024 EPS of (0.67) cents pre-consolidation restated ×10. FY2025–FY2026 per FY2026 Annual Report. Materials margin = revenue − raw materials consumed + change in inventories (company does not report gross profit under by-nature presentation). Statutory EBITDA = PBT + finance costs + D&A; adjusted EBITDA further adds back share-based payments (A$1.97m FY2026; A$1.21m FY2025), reconciling to the company's reported A$19.0m and A$7.0m. FY2024 loss includes an A$11.57m goodwill write-down; underlying FY2024 operating loss was A$1.41m (FY2025 Appendix 4E).
Margins
Note: FY2022–FY2024 gross margins use aggregator gross profit (cost-of-sales basis) and are not comparable with FY2025–FY2026 materials margins (by-nature basis, excluding labour).
Revenue CAGR: FY2022–FY2026 ≈ 256% (4-year; distorted by reverse-acquisition base); FY2023–FY2026 ≈ 143% (3-year); FY2024–FY2026 ≈ 177% (2-year).
FY2026 expense structure (by nature)
Commentary: Operating leverage is visible in fixed-cost lines—employee costs grew 120% against revenue growth of 161%, and "other expenses" rose only 9%. Variable costs (raw materials, commission, freight) grew broadly in line with or faster than revenue, compressing the materials margin by ~4 percentage points, consistent with a mix shift toward contract manufacturing and international supply (ADREX pricing) relative to higher-margin own-brand domestic sales. Marketing expense more than quadrupled as international brand activity (Dr Watson in Germany/UK) ramped. FY2026 benefited from an A$0.24m tax benefit (recognition of deferred tax assets on Australian losses), so pre-tax earnings are the better quality measure; the Australian tax group moved from a 25% base-rate entity to the 30% full rate, and with unrecognised Australian losses now largely used (A$4.0m remaining unrecognised overseas-related losses vs. A$23.8m a year earlier), a normalised tax charge should emerge in FY2027.
Half-year progression
Sources: H1 FY2025 and H1 FY2026 per company results releases; H2 figures derived as full year less H1. The H1 FY2026 presentation charts H1 FY2025 adjusted EBITDA as A$3.5m and H2 FY2025 as A$1.9m on a different basis—a discrepancy versus the A$3.7m originally reported and versus the restated FY2025 full-year A$7.0m.
Balance sheet
Source: FY2026 Annual Report, Consolidated Statement of Financial Position. Negative net debt denotes net cash.
Commentary: The balance sheet nearly tripled in FY2026. The dominant movement was inventory (+A$14.2m to A$17.8m), which the Board attributes to stock held against forecast demand, continuity-of-supply obligations and larger international programmes (notably ADREX). Right-of-use assets rose ~A$3.9m, consistent with expanded Brisbane premises (lease to February 2029 with a five-year option recognised). Debt remains modest: a 9.5% bank loan secured over Meadowbrook premises fit-out, 8–9% equipment finance, the £500k SOSE loan (9.5%, 60 months, nine-month capital holiday), and a product loan forgiven if product is unsold. Intangibles are negligible following the FY2024 goodwill write-off, so book equity is almost entirely tangible. Accumulated losses of A$10.7m flipped to retained earnings of A$4.4m.
Cash flow
Source: FY2026 Annual Report. FY2026 capex is gross of A$0.45–0.5m SOSE grant receipts netted in investing flows. Lease principal repayments sit in financing and are not deducted from the FCF measure above.
Commentary: Cash conversion weakened sharply—OCF fell to 28% of adjusted EBITDA (FY2025: ~90%) as working capital absorbed ~A$13m. The June 2026 quarter was a turning point, generating record OCF of ~A$6.3m, implying the first nine months of FY2026 consumed ~A$0.9m of operating cash. Management states supplier terms are being improved and expects better cash generation in FY2027. Equity funding in FY2026 was minor (option conversions A$1.34m; placement A$0.11m), so growth has been largely self-funded.
Ratios
Derivations by analyst from FY2026 Annual Report data. ROIC uses EBIT × (1 − 25% FY2025 / 30% FY2026) over equity + debt incl. leases − cash. Working-capital days use materials cost (raw materials less inventory change) as the COGS proxy; payables include non-trade items, so DPO is overstated. These ratios are indicative only.
Commentary: Returns are exceptionally high for a manufacturer because the asset base is light (leased facility, small PP&E) and equity was depressed by historical losses. The deterioration in the cash conversion cycle from roughly neutral to ~129 days is the single most important financial trend to monitor: inventory days almost doubled while payables days shortened. Receivables quality also softened modestly—the expected-credit-loss allowance rose to A$0.37m, with A$0.41m of receivables more than two months overdue (60% provisioned).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Function (as disclosed or inferred from disclosures) |
|---|---|---|
BLS Pharmaceuticals Limited | Australia | Listed parent, head of tax-consolidated group |
Breathe Life Sciences Pty Ltd | Australia | Operating group holding / brand owner |
BLS Wholesalers Pty Ltd | Australia | Licensed (TGA, ODC, QLD Health) manufacturer and wholesaler |
BLS Panther Pty Ltd | Australia | — |
Breathe Life Science UK Ltd | United Kingdom | UK operations; Scottish facility; borrower under SOSE loan |
Always Pure Organics EU | Czech Republic | European operations (Czechia expansion plans on hold) |
Mirai Solution Co KK | Japan | Japanese consumer health operations |
Dr Watson Japan KK | Japan | Dr Watson brand, Japan |
Global Treasure New Zealand Ltd; New Zealand Nutritional Research Institute Ltd; Bioxyne International (NZ) Ltd | New Zealand | Legacy entities (non-controlling interest acquired FY2026) |
Bioxyne International Malaysia Sdn Bhd; P.T. Gamata Utama | Malaysia; Indonesia | Discontinued SE Asia direct selling; being deregistered |
Bioxyne International Pty Ltd | Australia | Legacy direct-selling entity |
“—” = not publicly disclosed.
Revenue by Segment
| Segment (as reconstructable) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from customers (AUD Mn) | 9.66 | 28.43 | 74.16 |
PCC probiotic wholesale revenue (AUD Mn) | — | — | 0.55 |
Pharmaceutical manufacturing and distribution, derived (AUD Mn) | — | — | 73.61 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Quarterly)
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|---|
Revenue (AUD Mn) | 14.0 | 17.3 | 21.4 | 21.7 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD Mn) | 0.46 | 5.16 | 9.66 | 28.43 | 74.16 |
Revenue growth (%) | — | 1,013 | 87 | 194 | 161 |
Gross profit per aggregator (AUD Mn) | 0.14 | 1.90 | 3.40 | — | — |
Materials margin, derived (AUD Mn) | — | — | — | 17.10 | 41.56 |
Operating income / EBIT (AUD Mn) | -0.50 | -2.15 | -13.30 | 5.03 | 15.62 |
Statutory EBITDA (AUD Mn) | — | — | — | 5.81 | 17.00 |
Adjusted EBITDA, company definition (AUD Mn) | — | — | — | 7.01 | 18.97 |
Profit before tax (AUD Mn) | -0.49 | -1.96 | -13.00 | 4.90 | 15.16 |
Net income attributable (AUD Mn) | -0.49 | -1.94 | -13.33 | 4.90 | 15.40 |
Basic EPS, post-consolidation (A$ cents) | — | — | -6.7 | 2.4 | 6.9 |
Diluted EPS, post-consolidation (A$ cents) | — | — | -6.7 | 2.3 | 6.7 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross / materials margin (%) | 29.1 | 36.8 | 35.2 | 60.1 | 56.0 |
EBIT margin (%) | — | -41.7 | -137.7 | 17.7 | 21.1 |
Statutory EBITDA margin (%) | — | — | — | 20.4 | 22.9 |
Adjusted EBITDA margin (%) | — | — | — | 24.7 | 25.6 |
Net margin (%) | -106.5 | -37.6 | -138.0 | 17.2 | 20.8 |
Expense line (AUD Mn)
| Expense line (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Raw materials and consumables used | 12.10 | 36.70 |
Change in inventories (credit) | 0.77 | 4.10 |
Employee benefits and labour hire | 5.13 | 11.30 |
Commission | 0.73 | 1.84 |
Freight and transportation | 0.92 | 1.83 |
Marketing | 0.41 | 1.84 |
Subscriptions and data | 0.00 | 1.05 |
Professional and consulting fees | 1.06 | 1.35 |
Depreciation and amortisation | 0.78 | 1.39 |
Share-based payments | 1.21 | 1.97 |
Impairment of receivables | 0.00 | 0.25 |
Finance costs | 0.13 | 0.46 |
Other expenses | 2.71 | 2.95 |
Income Statement
| Metric | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 |
|---|---|---|---|---|
Revenue (AUD Mn) | 12.6 | 15.8 | 31.3 | 42.9 |
Adjusted EBITDA (AUD Mn) | 3.7 | 3.3 | 8.3 | 10.7 |
NPAT (AUD Mn) | — | — | 7.3 | 8.1 |
Balance Sheet and Per-Share Data
| Metric | FY2025 | FY2026 |
|---|---|---|
Total assets (AUD Mn) | 19.58 | 52.08 |
Cash and equivalents (AUD Mn) | 7.67 | 13.29 |
Trade receivables (AUD Mn) | 2.35 | 7.65 |
Inventories (AUD Mn) | 3.61 | 17.82 |
Plant and equipment (AUD Mn) | 2.33 | 5.09 |
Right-of-use assets (AUD Mn) | 1.04 | 4.97 |
Goodwill and intangibles (AUD Mn) | 0.39 | 0.39 |
Borrowings, current (AUD Mn) | 0.07 | 1.09 |
Borrowings, non-current (AUD Mn) | 0.28 | 1.93 |
Lease liabilities, total (AUD Mn) | 1.19 | 5.41 |
Total debt incl. leases (AUD Mn) | 1.53 | 8.43 |
Net debt incl. leases (AUD Mn) | -6.13 | -4.86 |
Net debt excl. leases (AUD Mn) | -7.32 | -10.27 |
Trade and other payables (AUD Mn) | 4.77 | 9.66 |
Contract liabilities (AUD Mn) | 1.06 | 2.66 |
Total current assets (AUD Mn) | 15.74 | 41.21 |
Total current liabilities (AUD Mn) | 6.40 | 14.22 |
Working capital (AUD Mn) | 9.34 | 26.99 |
Total equity (AUD Mn) | 12.10 | 31.09 |
NTA per share, post-consolidation (A$ cents) | 5.4 | 13.3 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | 6.28 | 5.41 |
Capex, PP&E gross (AUD Mn) | — | — | — | 2.10 | 3.80 |
Net investing cash flow (AUD Mn) | — | — | — | -2.07 | -3.55 |
Free cash flow, OCF less net investing (AUD Mn) | — | — | — | 4.21 | 1.87 |
Net financing cash flow (AUD Mn) | — | — | — | 2.42 | 3.76 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Cash receipts from customers (AUD Mn) | — | — | — | — | 76.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE, closing equity (%) | 40.5 | 49.5 |
ROE, average equity (%) | — | 71.3 |
ROA, closing assets (%) | 25.0 | 29.6 |
ROIC, notional NOPAT / invested capital (%) | 63.2 | 41.7 |
Current ratio (x) | 2.46 | 2.90 |
Quick ratio, per Eulerpool (x) | 1.18 | 1.90 |
Debt / equity incl. leases (x) | 0.13 | 0.27 |
Net debt / adjusted EBITDA (x) | -0.87 | -0.26 |
Interest coverage, EBIT / finance costs (x) | 39.3 | 33.9 |
Asset turnover, closing assets (x) | 1.45 | 1.42 |
Days sales outstanding (days) | 30 | 38 |
Days inventory outstanding, on materials cost (days) | 116 | 199 |
Days payables outstanding, on materials cost (days) | 154 | 108 |
Cash conversion cycle (days) | -8 | 129 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total group revenue (AUD Mn) | 9.66 | 28.43 | 74.16 |
Germany, ADREX shipments H1 only (AUD Mn) | — | — | 2.7 |
Costa Rica, initial commercial sale (AUD Mn) | — | — | 0.5 |
PCC probiotic wholesale, global (AUD Mn) | — | — | 0.55 |
Share Price & Returns
| Period | Return (%) | Start price (AUD) |
|---|---|---|
1 month | -11.7 | 0.94 |
3 months | 38.3 | 0.60 |
Year to date (from 31 Dec 2025) | 97.6 | 0.42 |
1 year | 80.4 | 0.46 |
3 years | 361.1 | 0.18 |
5 years | 196.4 | 0.28 |
Since inception (Apr 2012 data start) | -39.1 | 1.33 |
Share Price
| Metric | FY2025 | FY2026 |
|---|---|---|
Approx. year-end share price, post-consolidation (AUD) | 0.46 | 0.94 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | A$202m | 229.98m shares |
Enterprise value | A$197m | Market cap − cash A$13.3m + borrowings A$3.0m + leases A$5.4m |
Trailing P/E | 13.1x | FY2026 NPAT A$15.4m (includes A$0.24m tax benefit) |
Trailing P/E, tax-normalised at 30% | 19.1x | PBT A$15.16m × 0.7 |
EV / adjusted EBITDA (trailing) | 10.4x | A$19.0m |
EV / adjusted EBITDA (FY2027 guidance midpoint) | 7.3x | A$110m × 24.5% ≈ A$27m |
EV / sales (trailing) | 2.7x | A$74.2m |
EV / sales (FY2027 midpoint) | 1.8x | A$110m |
P / book | 6.5x | Net assets A$31.1m |
Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Shares on issue at year end, post-consolidation basis (M) | — | — | — | — | 229.98 |
Capital Markets
| Item | Detail |
|---|---|
Credit ratings (Moody's/S&P/Fitch) | None — unrated |
Bank loan | ~A$0.7m, 9.5%, 60-month term, secured over Meadowbrook fit-out |
SOSE project loan | £500k (≈A$1.0m), 9.5%, 60 months from Dec 2025, 9-month capital holiday |
Equipment finance and product loan | ~A$1.3m combined, 8–9% (product loan forgiven if product unsold) |
Lease liabilities | A$5.4m (Brisbane lease to Feb 2029 plus 5-year option) |
Overdraft | A$3.0m Westpac, undrawn (post year end) |
Maturity profile (AUD Mn) | Current (FY2027) |
Borrowings | 1.09 |
Lease liabilities | 0.56 |
Analyst Conclusions
Management guidance
FY2027 revenue of A$105–115m (+42% to +55%) and adjusted EBITDA margin of 23–26% (implied A$24–30m adjusted EBITDA), underpinned by continued Australian demand on spare capacity, execution of the ADREX contract, completion of the Scottish facility (by end 2026), and a favourable regulatory backdrop for cannabis, MDMA and psilocybin medicines. The Board also expects improved cash generation through better supplier terms. No consensus exists to compare against.
Bull case
-
Embedded growth is largely contracted or capacity-backed. The ADREX minimum (A$25m in the first 12 months) plus a full year of Aurora and Curaleaf QMID supply covers a large part of the A$31–41m revenue uplift implied by guidance, while Brisbane runs at roughly 30% of estimated revenue capacity.
-
Valuation is undemanding if guidance is met. At ~7x FY2027 EV/EBITDA midpoint for a business compounding revenue above 40% with 20%+ ROE and net cash, a re-rating toward specialty-pharma CDMO multiples is plausible as the rebrand, Frankfurt listing and consolidation broaden the investor base.
-
Psychedelic and international optionality is underpriced. BLS is an early GMP supplier of MDMA and psilocybin with a Cayman Chemical channel and a UK facility (c.A$150m capacity) coming online, giving exposure to strategic interest evidenced by large pharma transactions in psychedelics.
Bear case
-
Earnings quality and cash conversion. OCF covered only 28% of adjusted EBITDA; inventory quintupled to A$17.8m; reporting has required several restatements, a revised 4C and an auditor change. If inventory does not convert, FY2027 could require external funding.
-
Concentration and regulatory fragility. Revenue depends on Australian prescribing pathways and a small number of contracts (NectarTek terminable on six months' notice; ADREX a single German channel). A TGA policy shift or loss of one partner could erase a large share of growth.
-
Margin pressure and tax normalisation. Materials margin fell four points as mix shifted to contract and export supply; guidance already allows margins to slip to 23%; and a full 30% tax charge means EPS growth will lag EBITDA growth in FY2027.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q1 FY2027 4C: revenue run-rate vs. A$26–29m/quarter needed for guidance; inventory drawdown; OCF |
| Nov 2026 | AGM: remuneration vote (first-strike risk), Board renewal |
| Q4 CY2026 | Scotland facility completion and UK Home Office/MHRA licensing (~Dec 2026) |
| Ongoing | ADREX order flow against A$25m year-one minimum |
| Feb 2027 | H1 FY2027 results; guidance reaffirmation/upgrade |
| 26 Mar 2027 | Expiry of A$0.50 options (4.25m) — potential A$2.1m inflow |
| Ongoing | TGA/Australian regulatory developments on medicinal cannabis prescribing and driving laws |
| Ongoing | Any acquisition announcement (Board assessing opportunities) |
| Ongoing | New international partners (UK, EU, LATAM, potential US export pathway for psychedelics) |
| Ongoing | Sell-side coverage initiation post rebrand |
Analyst verdict
BLS Pharmaceuticals has completed one of the more striking transformations on the ASX small-cap board: from a sub-A$1m-revenue probiotic and direct-selling shell to a profitable, A$74m-revenue licensed manufacturer of controlled medicines in three years. The core thesis is sound and evidenced. Its licence stack across cannabis, MDMA and psilocybin is genuinely scarce, its downstream, asset-light model has produced a 26% adjusted EBITDA margin on modest capital, and management has repeatedly met or beaten guidance. FY2027 guidance of A$105–115m appears credible given contracted German volumes and substantial spare Brisbane capacity, and the stock's implied forward multiple (~7x EV/EBITDA at around A$0.88) does not demand heroic assumptions.
The investment case, however, is now less about growth than about quality. FY2026 exposed three weaknesses that a larger institutional audience will scrutinise: poor cash conversion driven by a five-fold inventory build; a run of reporting inconsistencies (multiple FY2025 revenue figures, restated presentation, a revised cash-flow report, a gap between unaudited and audited revenue, and a mid-year auditor change); and a governance structure—half-independent board, no standing committees, founder holding about a quarter of shares—that is light for a company approaching a A$200m valuation and operating in heavily regulated markets. Disclosure on customer concentration, geography and segment profitability is also thin relative to the risks.
On balance, BLS screens as an attractive but higher-risk compounder: the operating platform and contracts justify a constructive view, while the balance of evidence argues for position sizing that respects regulatory concentration and execution risk. The decisive datapoints over the next two quarters are inventory conversion into cash, ADREX order delivery against minimums, and licensing of the Scottish facility. Delivery on all three, alongside committee formation and fuller segment disclosure, would materially de-risk the story and support a re-rating; slippage on cash conversion would quickly shift the narrative toward funding risk.
It is not financial advice. Figures marked as derived are analyst calculations from company filings; aggregator data is flagged where used and may contain errors. Verify current share price and any announcements after 31 August 2026 before relying on this analysis.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education |
|---|---|---|---|---|
Anthony (Tony) Ho | Non-Executive Independent Chairman | 30 Oct 2012 | Former executive director of Arthur Yates & Co (retired 2002); CFO/finance director roles at M.S. McLeod Holdings, Galore Group, Edward H O'Brien group; former partner of Cox Johnston & Co (now EY). Chairman of NZX/ASX-listed Truscreen Group; former chairman of Cannasouth, Energy Transition Minerals, Credit Intelligence; former NED of Hastings Technology Metals | B.Com (UNSW); Grad Dip Marketing (UTS); CA; FAICD; FCG(CS); FGIA |
Samuel (Sam) Watson | Managing Director and CEO | 19 May 2023 | Founder of Breathe Life Sciences and Dr Watson brand (2018); CEO and founder of Breathe International Ltd (largest shareholder) | BSc Finance and Economics (NYU Stern) |
Jason Hine | Executive Director and COO | 19 May 2023 | Former GM Commercial Operations, ECS Botanics (ASX medicinal cannabis/hemp); 30-year career including executive directorships across manufacturing, power distribution, finance, consulting | — |
Edward (Ed) Myer | Non-Executive Director (described as independent in Q4 FY2026 report) | 3 Jun 2026 | Investor/executive via MWP Partners Ltd; capital markets experience with global investment banks in London, Hong Kong and Australia | B.Bus (Marketing, Monash); Grad Dip Applied Finance (Macquarie); GAICD |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Sam Watson | CEO / MD | 2023 (BLS since 2018) | See above |
Jason Hine | COO | 2023 | See above |
Guy Robertson | CFO and Company Secretary | 1 Sep 2016 | 30+ years as director/CFO/Co Sec in Australia, NZ and Hong Kong; Jardine Matheson group roles including GM Finance Franklins Supermarkets, COO/CFO Colliers Jardine Asia Pacific, CFO and MD (NSW) Jardine Lloyd Thompson. B.Com (Hons), CA |
Jason Stephens | Senior officer (among top five remunerated, non-KMP) | — | — |
Macdarragh O'Neill | Senior officer (among top five remunerated, non-KMP) | — | — |
“—” = not publicly disclosed.
Directors' Shareholdings
| Executive | Fixed package from 1 Jul 2025 (AUD) | Notice | FY2026 performance rights granted (tranches) |
|---|---|---|---|
Sam Watson | 350,000 | 6 months | Share-price (>A$0.60, >A$0.80 post-consolidation), FY2026/FY2027 revenue and EBITDA targets, individual KPIs |
Jason Hine | 240,000 | 3 months | As above |
Guy Robertson | 141,600 | 1 month | As above |
Governance Overview
| Attribute | Status |
|---|---|
Board size | 4 |
Independent directors | 2 of 4 (Ho; Myer) — not a majority independent board (ASX Recommendation 2.4 not met on this basis) |
Chair/CEO separation | Yes; independent chair |
Committees | None separately constituted; full Board performs audit & risk and remuneration & nomination functions |
Board meetings FY2026 | 11 (full attendance by all directors in office) |
Governance framework | ASX Corporate Governance Principles (4th ed.); statement approved 28 August 2026 |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Breathe International Limited (controlled by Sam Watson) | 26.53% (576,268,527 shares pre-consolidation ≈ 57.6m post) | Substantial holder notice per InvestSMART |
Total KMP holdings (incl. Watson-controlled Breathe International and Zonetech Wellness) | 72,893,447 shares at 30 June 2026 ≈ 31.7% of issued capital | FY2026 Annual Report |
Directors' total holdings at report date | 71,382,947 shares; 4,900,000 performance rights; 20,000 options | FY2026 Annual Report |
Other substantial holders / top-20 holders | Not publicly disclosed in sources reviewed (contained in Annual Report shareholder information section) | — |
Institutional ownership | Not publicly disclosed; company references a growing institutional and international shareholder base. Not held by any ETFs (InvestSMART) | — |
Board & Management Changes
| Date | Change |
|---|---|
19 May 2023 | Sam Watson and Jason Hine join Board on BLS acquisition |
29 Jan 2026 | Auditor changed: RSM Australia → Pitcher Partners |
3 Jun 2026 | Edward Myer appointed NED |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type / listing | Relative positioning vs. BLS |
|---|---|---|---|
Australian medicinal cannabis manufacturing | Little Green Pharma | ASX-listed; vertically integrated cultivator/manufacturer (AU, Denmark) | Owns cultivation; BLS is asset-lighter, broader dose-form and controlled-drug scope |
Australian medicinal cannabis manufacturing | Cann Group | ASX-listed; cultivator/manufacturer | Cultivation-heavy, capital intensive; BLS avoids cultivation risk |
Australian medicinal cannabis | ECS Botanics | ASX-listed; Tasmanian cultivator, hemp foods | COO Jason Hine is ex-ECS; cultivation-led |
Australian medicinal cannabis distribution / brands | Montu | Private; large telehealth/distribution platform | Prescribing/distribution channel—potential customer and competitor for own-brand sales |
Australian medicinal cannabis distribution | Vitura Health | ASX-listed; distribution, telehealth (Canview) | Channel-focused; BLS is manufacturing-focused |
Global cannabis majors in Australia | Curaleaf International; Aurora Cannabis; Tilray | Listed (TSX/Nasdaq/CSE) | Currently BLS partners/customers (Curaleaf, Aurora); could in-source or switch |
Psychedelic API / finished-dose supply into Australia | Optimi Health | CSE-listed (Canada); MDMA/psilocybin GMP supplier | Direct competitor for Authorised Prescriber supply |
Psychedelic API / natural psilocybin | Filament Health | Listed (Canada); natural psilocybin drug candidates | Competitor in psilocybin supply |
Psychedelic drug development | Compass Pathways (psilocybin COMP360); MindMed; Gilgamesh (acquired by AbbVie) | Nasdaq / big pharma | Drug developers rather than CDMOs; potential future customers or competitors if approved products displace compounded/SAS supply |
Australian psychedelic clinics | Emyria | ASX-listed; MDMA-assisted therapy clinics | Downstream; potential customer |
UK cannabis-based medicinal products | UK licensed manufacturers/importers (e.g., Grow Pharma, Curaleaf UK) | Private / listed | BLS UK facility will compete for UK GMP manufacture |
German medical cannabis | Demecan, Aurora Deutschland, Cantourage, Tilray Germany | Private / listed | ADREX channel competes for German pharmacy share |
Competitor Detail
| Metric | BLS Pharmaceuticals |
|---|---|
Latest FY revenue (AUD Mn) | 74.2 |
Revenue growth (%) | 161 |
Adjusted EBITDA margin (%) | 26 |



